Multiple Sclerosis Trial, Recruiting (NCT06312046)

Multiple Sclerosis Trial, Recruiting NCT06312046 Sponsor: Karolinska Institutet Condition: Multiple Sclerosis

Printed from Voxsanity (voxsanity.com.au) — NCT06312046 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Multiple Sclerosis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with Multiple Sclerosis (MS) using a standard set of medical criteria known as the McDonald criteria.
People whose level of MS-related disability falls within a specific mid-range on a standard medical scale called the Expanded Disability Status Scale (scores between 2.0 and 5.5).
People who are able to walk at least 100 metres without using a walking aid.
People who score below 25 points on a balance assessment test called the Mini-BESTest.
People who are between 18 and 65 years of age.

Who may not be able to join:

People whose results on a memory and thinking assessment called the Montreal Cognitive Assessment fall below a score of 21, which may indicate cognitive difficulties.
People who have other health conditions that would significantly affect their balance.
People who have had an MS relapse, or who have had a change to their MS medication, within the past 8 weeks.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sverker Johansson, Ph.D, Karolinska Institutet, org.nr 202100-2973

Phone: +46852480000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06312046

Sponsor: Karolinska Institutet

Phase: Not Applicable

Status: Recruiting

Condition: Multiple Sclerosis

Trial contact: +46852480000

More information: https://clinicaltrials.gov/study/NCT06312046

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with Multiple Sclerosis (MS) using a standard set of medical criteria known as the McDonald criteria.
People whose level of MS-related disability falls within a specific mid-range on a standard medical scale called the Expanded Disability Status Scale (scores between 2.0 and 5.5).
People who are able to walk at least 100 metres without using a walking aid.
People who score below 25 points on a balance assessment test called the Mini-BESTest.
People who are between 18 and 65 years of age.

Who may not be able to join:

People whose results on a memory and thinking assessment called the Montreal Cognitive Assessment fall below a score of 21, which may indicate cognitive difficulties.
People who have other health conditions that would significantly affect their balance.
People who have had an MS relapse, or who have had a change to their MS medication, within the past 8 weeks.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Karolinska Institutet

Registry

ClinicalTrials.gov

Start date

26 February 2024

Est. completion

31 December 2025

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Mini Balance Evaluation Systems test.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov